Zhejiang Jianfeng Group (600668.SH) announced that the holding subsidiary of its wholly-owned subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd....
Finance and Economics App News, Jianfeng Group (600668.SH) announced that its wholly-owned subsidiary Zhejiang Jianfeng Pharmaceutical Co., Ltd.'s holding subsidiary Zhejiang Er Ying Pharmaceutical Co., Ltd. ('Er Ying Company') received the approval notice for the supplementary application of 10mg and 20mg specifications of esomeprazole magnesium enteric-coated granules for suspension (DPAS), issued by the National Medical Products Administration. This marks that Jianfeng Pharmaceutical and its subsidiary Er Ying Company have added two specifications of 10mg and 20mg to the original 40mg specification of esomeprazole magnesium enteric-coated granules for suspension (DPAS).
It is reported that esomeprazole magnesium is used clinically for the treatment of reflux esophagitis; reduces the risk of NSAID-related gastric ulcers; and combined with appropriate antibacterial therapy to eradicate Helicobacter pylori and reduce the risk of duodenal ulcer recurrence; and pathological hypersecretory syndromes including Zollinger-Ellison syndrome. Esomeprazole magnesium enteric-coated granules for suspension (DPAS) is a special dosage form launched by Astrazeneca after tablets and capsules, which is suitable for patients who cannot or simply do not want to swallow capsules or tablets.